Trial reportBMC psychiatry2026
Exploring the feasibility, safety and preliminary clinical effects of amygdala-targeted temporal interference stimulation for major depressive disorder: a pilot study.
Trial report in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06461260 (Safety, Efficacy and Neuroimaging Mechanisms of Amygdala Temporal Interference Stimulation Therapy for Depression), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety, Efficacy and Neuroimaging Mechanisms of Amygdala Temporal Interference Stimulation Therapy for Depression
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTemporal interference stimulation (TIS) is a novel noninvasive neuromodulation technique. However, whether it can be applied in patients with major depressive disorder (MDD) remains unclear. This pilot study investigated the feasibility, safety, and preliminary clinical effects of amygdala-targeted TIS in patients with MDD.
methodsIn this single-center, single-arm pilot study, 32 MDD patients received a 5-day amygdala-targeted TIS. The primary outcomes were feasibility (defined by the intervention completion rate) and safety (evaluated through participant-reported adverse events). The secondary outcomes assessed preliminary clinical efficacy, including changes in depressive symptoms measured by the 17-item Hamilton Depression Rating Scale (HAMD-17) and Montgomery-Åsberg Depression Rating Scale (MADRS), as well as anxiety, anhedonia, sleep quality, and health-related quality of life. Assessments were performed at baseline, postintervention, and at the 1-week and 1-month follow-ups. Statistical analyses included mainly linear mixed-effects models and paired t tests.
resultsAll participants completed the full intervention while maintaining stable psychiatric medication. TIS was well tolerated, with mostly mild adverse events (sleepiness, 24.1%; dizziness, 14.1%; unusual scalp sensations, 10.5%) and no serious safety concerns. The HAMD-17 response rates were 59.4% post-intervention, 65.4% at the 1-week follow-up, and 50.0% at the 1-month follow-up. The corresponding MADRS response rates were 54.8%, 65.4%, and 53.3%, respectively. Significant improvements were also observed in anxiety, anhedonia, sleep quality, and quality of life.
conclusionsThis pilot study suggests that amygdala-targeted TIS is feasible, well tolerated, and associated with promising clinical improvements in patients with MDD, warranting further investigation in randomized controlled trials.
trial registrationThis study has been prospectively registered at ClinicalTrials.gov on June 14, 2024 (Registration ID: NCT06461260).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.